Varied effects of doxorubicin (DOX) on the corpus luteum of C57BL/6 mice during early pregnancy†.


Journal

Biology of reproduction
ISSN: 1529-7268
Titre abrégé: Biol Reprod
Pays: United States
ID NLM: 0207224

Informations de publication

Date de publication:
20 12 2021
Historique:
received: 28 05 2021
revised: 22 08 2021
pubmed: 24 9 2021
medline: 21 1 2022
entrez: 23 9 2021
Statut: ppublish

Résumé

Certain chemotherapeutic drugs are toxic to ovarian follicles. The corpus luteum (CL) is normally developed from an ovulated follicle for producing progesterone (P4) to support early pregnancy. To fill in the knowledge gap about effects of chemotherapy on the CL, we tested the hypothesis that chemotherapy may target endothelial cells and/or luteal cells in the CL to impair CL function in P4 steroidogenesis using doxorubicin (DOX) as a representative chemotherapeutic drug in mice. In both mixed background mice and C57BL/6 mice, a single intraperitoneal injection of DOX (10 mg/kg) on 0.5-day postcoitum (D0.5, postovulation) led to ~58% D3.5 mice with serum P4 levels lower than the serum P4 range in the phosphate buffer saline-treated control mice. Further studies in the C57BL/6 ovaries revealed that CLs from DOX-treated mice with low P4 levels had less defined luteal cords and disrupted collagen IV expression pattern, indicating disrupted capillary, accompanied with less differentiated luteal cells that had smaller cytoplasm and reduced StAR expression. DOX-treated ovaries had increased granulosa cell death in the growing follicles, reduced proliferating cell nuclear antigen-positive endothelial cells in the CLs, enlarged lipid droplets, and disrupted F-actin in the luteal cells. These novel data suggest that the proliferating endothelial cells in the developing CL may be the primary target of DOX to impair the vascular support for luteal cell differentiation and subsequently P4 steroidogenesis. This study fills in the knowledge gap about the toxic effects of chemotherapy on the CL and provides critical information for risk assessment of chemotherapy in premenopausal patients.

Identifiants

pubmed: 34554181
pii: 6374379
doi: 10.1093/biolre/ioab180
pmc: PMC8689115
doi:

Substances chimiques

Antibiotics, Antineoplastic 0
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1521-1532

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD065939
Pays : United States
Organisme : NICHD NIH HHS
ID : R03 HD097384
Pays : United States
Organisme : NICHD NIH HHS
ID : R03 HD100652
Pays : United States
Organisme : NIH HHS
ID : P50-HD28934
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

J Clin Oncol. 2009 Jun 1;27(16):2677-85
pubmed: 19364965
Cell Tissue Res. 2015 Aug;361(2):427-38
pubmed: 25693894
Nat Rev Genet. 2006 Mar;7(3):185-99
pubmed: 16485018
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Crit Rev Oncol Hematol. 2016 Jan;97:206-19
pubmed: 26358422
Pharmacogenet Genomics. 2011 Jul;21(7):440-6
pubmed: 21048526
Amino Acids. 2012 May;42(5):1839-55
pubmed: 21476075
Science. 2001 Jul 27;293(5530):702-5
pubmed: 11474113
Drug Chem Toxicol. 2018 Jan;41(1):72-81
pubmed: 28441888
Semin Cell Dev Biol. 2014 Oct;34:65-75
pubmed: 24954643
Pediatr Blood Cancer. 2018 Nov;65(11):e27297
pubmed: 29972282
Arch Biochem Biophys. 1999 Feb 1;362(1):59-66
pubmed: 9917329
Cancer Chemother Pharmacol. 1981;5(4):267-70
pubmed: 7261254
Reprod Toxicol. 2014 Apr;44:85-92
pubmed: 24365114
JACC CardioOncol. 2020 Sep;2(3):475-488
pubmed: 33073250
Breast Cancer Res Treat. 2020 Jul;182(2):325-332
pubmed: 32462261
Toxicol Sci. 2018 May 1;163(1):279-292
pubmed: 29462422
Biochim Biophys Acta. 2016 Aug;1861(8 Pt B):793-805
pubmed: 26713677
Biol Reprod. 2018 Apr 1;98(4):570-578
pubmed: 29236949
Nature. 1990 Nov 29;348(6300):455-8
pubmed: 1978929
Reprod Biol Endocrinol. 2003 Nov 10;1:89
pubmed: 14613535
Cancer Chemother Pharmacol. 2021 Apr;87(4):567-578
pubmed: 33471160
Int J Cell Biol. 2012;2012:282041
pubmed: 22536247
PLoS One. 2017 Mar 3;12(3):e0173429
pubmed: 28257503
J Biol Chem. 2000 Oct 27;275(43):33585-92
pubmed: 10899161
Endocrinology. 2018 May 1;159(5):2094-2109
pubmed: 29554271
Biol Reprod. 1998 Feb;58(2):330-7
pubmed: 9475386
Biol Reprod. 2019 Apr 1;100(4):869-871
pubmed: 30561525
Cancers (Basel). 2020 May 18;12(5):
pubmed: 32443608
Am J Physiol. 1996 Nov;271(5 Pt 2):H2079-85
pubmed: 8945928
Int J Clin Oncol. 2019 Jan;24(1):28-33
pubmed: 29502284
Endocrine. 2014 Aug;46(3):615-23
pubmed: 24366645
Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1271-4
pubmed: 528276
Cell Rep. 2020 Jun 30;31(13):107824
pubmed: 32610125
Sci Rep. 2020 Jul 9;10(1):11287
pubmed: 32647143
Nature. 2005 May 5;435(7038):104-8
pubmed: 15875025
Reprod Biol Endocrinol. 2003 Nov 10;1:90
pubmed: 14613534
In Vivo. 2012 Sep-Oct;26(5):827-34
pubmed: 22949597
Endocr Rev. 2019 Apr 1;40(2):369-416
pubmed: 30496379
PLoS One. 2015 Jul 02;10(7):e0131763
pubmed: 26134406
Biomed Mater Eng. 2014;24(1):909-16
pubmed: 24211979
Reprod Toxicol. 2014 Nov;49:48-54
pubmed: 25062584
Mol Hum Reprod. 2009 Jun;15(6):321-33
pubmed: 19321517
Trends Endocrinol Metab. 2020 Feb;31(2):165-180
pubmed: 31866217
Toxicol Sci. 2019 May 1;169(1):43-53
pubmed: 30657998
Biochem Biophys Rep. 2021 Jan 30;25:100926
pubmed: 33553688
Biol Reprod. 2019 Oct 25;101(4):782-790
pubmed: 31317194
J Biol Chem. 1986 Mar 5;261(7):3060-7
pubmed: 3456345
Sci Rep. 2021 Mar 9;11(1):5522
pubmed: 33750916
J Lipid Res. 1977 Mar;18(2):246-58
pubmed: 845506
Chemotherapy. 2014;60(1):24-36
pubmed: 25341697
Lancet Oncol. 2016 May;17(5):567-76
pubmed: 27020005
Toxicol Appl Pharmacol. 2019 Oct 15;381:114714
pubmed: 31437492
Toxicol Sci. 2017 Jun 1;157(2):320-329
pubmed: 28329872
Endocrinology. 2008 Aug;149(8):3942-51
pubmed: 18420734
J Reprod Fertil. 1969 Jul;19(2):223-9
pubmed: 5815725
Nat Med. 2013 Aug;19(8):1061-6
pubmed: 23817023
Endocrinology. 2017 Jul 1;158(7):2168-2178
pubmed: 28498971
Mol Hum Reprod. 2010 Mar;16(3):135-52
pubmed: 19880575
Br J Cancer. 1999 Jan;79(1):108-13
pubmed: 10408701
Am J Anat. 1988 Apr;181(4):393-400
pubmed: 3389306
Toxicol Sci. 2013 Apr;132(2):431-42
pubmed: 23291560
FASEB J. 2020 Oct;34(10):13885-13899
pubmed: 32830364

Auteurs

Christian Lee Andersen (CL)

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Interdisciplinary Toxicology Program, University of Georgia, Athens, Georgia, USA.

Haeyeun Byun (H)

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.

Yuehuan Li (Y)

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.

Shuo Xiao (S)

Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA.

Doris M Miller (DM)

Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.

Zidao Wang (Z)

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Interdisciplinary Toxicology Program, University of Georgia, Athens, Georgia, USA.

Suvitha Viswanathan (S)

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.

Jonathan Matthew Hancock (JM)

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Interdisciplinary Toxicology Program, University of Georgia, Athens, Georgia, USA.

Jaymie Bromfield (J)

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.

Xiaoqin Ye (X)

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Interdisciplinary Toxicology Program, University of Georgia, Athens, Georgia, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH